Vascular endothelial growth factor

Diabetic Retinopathy Drug Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021
General Health, Pharmaceutical, Health, Brolucizumab, Clinical trial, Discovery, Diabetic retinopathy, Cerebral edema, Novartis, Route, Administration, Therapy, Fragment crystallizable region, Patient, Growth, Route of administration, NAV, Vascular endothelial growth factor, News, III, II, Drug development, Pharmaceutical industry

The "Diabetic Retinopathy - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Retinopathy - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Diabetic retinopathy - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diabetic retinopathy pipeline landscape.
  • This segment of the Diabetic retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Diabetic retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Wednesday, August 4, 2021
Visual system, Nervous system, Anatomy, Neuroscience, Retina, Optic nerve

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a panel discussion titled Goldeneye at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021 at 9:45 a.m.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a panel discussion titled Goldeneye at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021 at 9:45 a.m.
  • A live webcast of the panel will be available in the Investors and Media section of the companys website at https://investors.graybug.vision/news-events/events-presentations .
  • Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.
  • Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California.

Eyevensys Raises $12M in a Series B Plus Funding Round

Retrieved on: 
Wednesday, August 4, 2021
Health, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Wedbush Securities, Korea Investment Partners, Eyevensys, KOREA INVESTMENT PARTNERS, EYEVENSYS

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round.

Key Points: 
  • Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round.
  • Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
  • We're thrilled to announce this funding round, which will help us move forward in our mission to develop life-changing solutions for patients with debilitating eye diseases, said Dr. Patricia Zilliox, CEO of Eyevensys.
  • Wedbush PacGrow acted as the exclusive placement agent for the Series B Plus financing.

UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease

Retrieved on: 
Friday, July 23, 2021
Branches of biology, Senescence, Biology, Vascular endothelial growth factor, Macular degeneration, Senolytic

SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a webcast for investors and analysts on July 27, 2021 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss clinical data from the Phase 1 study in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) patients treated with a single injection of UBX1325.

Key Points: 
  • We look forward to having Dr. Bhisitkul share his insights and observations following the review of patient data and images.
  • We are excited to continue exploring this novel senolytic mechanism in DME and wet AMD patients as a potential disease-modifying alternative and complement to anti-VEGF treatments.
  • A parallel Phase 2a study in DME is currently enrolling, with information about that trial available here .
  • UNITY will host a conference call and webcast for investors and analysts on Tuesday, July 27, 2021, at 8:00 a.m. PT (11:00 a.m.

Stimulating blood vessel formation with magnets

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Angiology, Stem cells, Growth factors, Vascular endothelial growth factor, Biotechnology, Endothelium, Stromal cell, Mesenchymal stem cell, Cell therapy, Craniofacial regeneration

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Biology, Angiology, Medical specialties, Growth factors, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Vascular endothelial growth factor, Angiogenesis inhibitor, Angiogenesis

WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Key Points: 
  • WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.
  • OncXernas approach pairs those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Notal Vision announces publication of first prospective longitudinal pilot study of daily self-imaging with patient-operated Home OCT in wet AMD patients

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Ophthalmology, Clinical medicine, Angiology, Anti–vascular endothelial growth factor therapy, Macular degeneration, Vascular endothelial growth factor

The study evaluated the ability of subjects to perform sequential daily self-imaging of their eyes with the user-friendly, tele-connected and self-operated Notal Home OCT device in their homes.

Key Points: 
  • The study evaluated the ability of subjects to perform sequential daily self-imaging of their eyes with the user-friendly, tele-connected and self-operated Notal Home OCT device in their homes.
  • Led by Prof. Loewenstein, the pilot study in Israel followed four patients undergoing routine anti-VEGF therapy for wet AMD in one or both eyes for up to three months.
  • Prospective longitudinal pilot study: daily self-imaging with patient-operated home OCT in neovascular age-related macular degeneration.
  • Notal Visions Home OCT system will enable wet AMD patients to perform technician-free OCTtesting at home with rapid and self-guided fixation critical components, especially for elderly patients frequently with pre-existing vision loss.

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor, Diabetic retinopathy, Macular edema, Kallikrein, Conbercept

Dose selection data from Part A of the study is expected in the second half of 2021.

Key Points: 
  • Dose selection data from Part A of the study is expected in the second half of 2021.
  • THR-149 acts through inhibition of the plasma kallikrein-kinin (PKaI-Kinin) system, a validated VEGF-independent target for DME.
  • The Phase 2 KALAHARI study is a two part, randomized, prospective, multi-center study assessing multiple (3) injections of THR-149 in DME patients who suboptimally respond to anti-VEGF therapy.
  • This patient population currently does not have adequate treatment options and represents a critical area of unmet medical need in the treatment of diabetic macular edema.

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Clinical medicine, Medicine, Intravitreal administration, Ophthalmic drug administration, Vascular endothelial growth factor, Macular degeneration, Anti–vascular endothelial growth factor therapy

We are pleased to report the completion of enrollment of all three dose cohorts in our ongoing Phase 1 trial of EYP-1901, said Nancy Lurker, CEO of EyePoint Pharmaceuticals.

Key Points: 
  • We are pleased to report the completion of enrollment of all three dose cohorts in our ongoing Phase 1 trial of EYP-1901, said Nancy Lurker, CEO of EyePoint Pharmaceuticals.
  • The completion of enrollment of our Phase 1 trial continues to make us confident that the potential advantages of EYP-1901 are obvious to patients and providers.
  • The ongoing Phase 1 DAVIO trial for EYP-1901 is an open-label twelve-month dose escalation trial examining wet AMD patients who were responsive to previous anti-VEGF therapies.
  • EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration, currently being studied in a Phase 1 clinical trial.

aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Medical specialties, Medicine, Neuropilin 2, Immunology, Vascular endothelial growth factor, Monoclonal antibody, aTyr Pharma

ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.

Key Points: 
  • ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.
  • ATYR2810 is the first Investigational New Drug (IND) candidate to arise from aTyr\xe2\x80\x99s in-house research program designing monoclonal antibodies to selectively target the NRP2 receptor and its associated signaling pathways.
  • Preclinical data suggest that ATYR2810 could be effective against certain types of solid tumors.
  • aTyr\xe2\x80\x99s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.